Bevacizumab, olaparib i trabectedina per al tractament del càncer d'ovari epitelial avançat, trompa de Fal·lopi o peritoneal primari: informe d’avaluació de resultats
Abstract
Ovarian cancer is the fifth leading cause of cancer death in Europe in women and the leading cause of gynecological cancer. The initial treatment for ovarian cancer is platinum-based surgery and chemotherapy (QT). The frequency of relapses in advanced stages is around 60-80%, and in general, although there are other factors to consider, the patient is considered a candidate to receive platinum treatment if the relapse occurs more than 6 months of treatment. Platinum-based QT burns are again administered to patients in platinum relapse, which, if the complete or partial response is achieved, is followed by maintenance treatment. In contrast, in refractory patients (during first-line QT or <1 month) or resistant patients (relapse before 6 months), treatment options are more limited and the probability of response is lower.
Keywords
Ovarian cancer; Fallopian tube; Peritoneal cancer; Bevacizumab; Olaparib; Trabectedin; RPT
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Bevacizumab, olaparib i trabectedina per al tractament del càncer d'ovari epitelial avançat, trompa de Fal·lopi o peritoneal primari: informe d’avaluació de resultats. Barcelona: Servei Català de la Salut; 2021.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/5781This item appears in following collections
The following license files are associated with this item: